Citius Oncology, Inc.
CTOR
$0.94
$0.011.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -73.32% | -63.62% | -2.41% | -17.08% | -36.13% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 103.39% | 49.52% | 42.52% | 16.13% | 3.04% |
| Change in Net Operating Assets | -50.49% | -37.70% | -108.66% | -25.06% | 62.11% |
| Cash from Operations | -15,439.48% | -13,295.02% | -10,263.69% | -4,444.94% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -155.00% | -115.00% | -103.00% | -15.00% | -- |
| Cash from Investing | -155.00% | -115.00% | -103.00% | -15.00% | -- |
| Total Debt Issued | 153.55% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -183.14% | -115.77% | -- | -- | -- |
| Cash from Financing | 899.28% | 516.79% | 521.53% | 211.19% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16,563,500.00% | 2,632,400.00% | 7,295,200.00% | 3,924,700.00% | -- |